12 Health Care Stocks Witness Significant Movement in Tuesday's After-Market Session
PorAinvest
miércoles, 14 de mayo de 2025, 9:45 am ET1 min de lectura
APYX--
Gainers:
- Innovative Eyewear (LUCY): The stock increased by 57.2% to $2.94, with a market value of $8.9 million. The company reported its Q1 2025 unaudited financial results, showing revenue growth and margin improvements. Revenue reached $454,501, up 19% from Q1 2024, driven by new product launches including Nautica® and Eddie Bauer® collections. Gross profit margin significantly improved to 49% from 2% in Q1 2024. Despite these improvements, the company reported a net loss of $1,778,703, though smaller than Q1 2024's loss of $1,971,311 [3].
- Apyx Medical (APYX): The stock rose 42.98% to $1.58, with a market value of $59.7 million. The company's Q1 earnings came out 3 days ago [2].
- Xilio Therapeutics (XLO): The stock moved upwards by 40.9% to $1.03, with a market cap of $53.3 million. The company's Q1 earnings also came out 3 days ago [2].
- Omeros (OMER): The stock increased by 16.2% to $4.41, with a market cap of $255.5 million [2].
- Hims & Hers Health (HIMS): The stock moved upwards by 15.92% to $64.0, with a market value of $14.3 billion [2].
- Agape ATP (ATPC): The stock increased by 15.15% to $1.9, with a market cap of $95.0 million [2].
Losers:
- Polyrizon (PLRZ): The stock declined by 95.5% to $0.02 during Tuesday's after-market session [2].
- Accelerate Diagnostics (AXDX): The stock fell 44.08% to $0.07, with a market cap of $1.8 million [2].
- Regencell Bioscience (RGC): The stock decreased by 36.9% to $296.59, with a market cap of $3.8 billion [2].
- Halozyme Therapeutics (HALO): The stock fell 24.91% to $50.0, with a market value of $6.1 billion [2].
- Kindly MD (KDLY): The stock declined by 23.96% to $10.41, with a market value of $62.2 million. The company's Q1 earnings came out 3 days ago [2].
- Vivani Medical (VANI): The stock decreased by 20.39% to $0.82, with a market cap of $54.6 million. The company's Q1 earnings came out today [2].
These movements reflect the ongoing volatility in the healthcare sector, driven by various factors including earnings reports, market sentiment, and geopolitical events. Investors should continue to monitor these companies for further developments.
References:
[1] https://www.cnbc.com/2025/05/13/1-stock-we-just-initiated-and-3-others-get-nice-bumps-after-saudis-us-spending-spree.html
[2] https://www.benzinga.com/insights/movers/25/05/45392931/12-health-care-stocks-moving-in-tuesdays-after-market-session
[3] https://www.stocktitan.net/news/LUCY/innovative-eyewear-inc-reports-q1-2025-unaudited-financial-ufmaqq8mocwd.html
HIMS--
LUCY--
OMER--
XLO--
Healthcare stocks saw significant movements in Tuesday's after-market session. Gainers included Innovative Eyewear, Apyx Medical, Xilio Therapeutics, Omeros, Hims & Hers Health, and Agape ATP, while losers were Polyrizon, Accelerate Diagnostics, Regencell Bioscience, Halozyme Therapeutics, Kindly MD, and Vivani Medical.
Healthcare stocks experienced significant fluctuations in Tuesday's after-market session. Gainers included Innovative Eyewear (LUCY), Apyx Medical (APYX), Xilio Therapeutics (XLO), Omeros (OMER), Hims & Hers Health (HIMS), and Agape ATP (ATPC). Meanwhile, losers were Polyrizon (PLRZ), Accelerate Diagnostics (AXDX), Regencell Bioscience (RGC), Halozyme Therapeutics (HALO), Kindly MD (KDLY), and Vivani Medical (VANI).Gainers:
- Innovative Eyewear (LUCY): The stock increased by 57.2% to $2.94, with a market value of $8.9 million. The company reported its Q1 2025 unaudited financial results, showing revenue growth and margin improvements. Revenue reached $454,501, up 19% from Q1 2024, driven by new product launches including Nautica® and Eddie Bauer® collections. Gross profit margin significantly improved to 49% from 2% in Q1 2024. Despite these improvements, the company reported a net loss of $1,778,703, though smaller than Q1 2024's loss of $1,971,311 [3].
- Apyx Medical (APYX): The stock rose 42.98% to $1.58, with a market value of $59.7 million. The company's Q1 earnings came out 3 days ago [2].
- Xilio Therapeutics (XLO): The stock moved upwards by 40.9% to $1.03, with a market cap of $53.3 million. The company's Q1 earnings also came out 3 days ago [2].
- Omeros (OMER): The stock increased by 16.2% to $4.41, with a market cap of $255.5 million [2].
- Hims & Hers Health (HIMS): The stock moved upwards by 15.92% to $64.0, with a market value of $14.3 billion [2].
- Agape ATP (ATPC): The stock increased by 15.15% to $1.9, with a market cap of $95.0 million [2].
Losers:
- Polyrizon (PLRZ): The stock declined by 95.5% to $0.02 during Tuesday's after-market session [2].
- Accelerate Diagnostics (AXDX): The stock fell 44.08% to $0.07, with a market cap of $1.8 million [2].
- Regencell Bioscience (RGC): The stock decreased by 36.9% to $296.59, with a market cap of $3.8 billion [2].
- Halozyme Therapeutics (HALO): The stock fell 24.91% to $50.0, with a market value of $6.1 billion [2].
- Kindly MD (KDLY): The stock declined by 23.96% to $10.41, with a market value of $62.2 million. The company's Q1 earnings came out 3 days ago [2].
- Vivani Medical (VANI): The stock decreased by 20.39% to $0.82, with a market cap of $54.6 million. The company's Q1 earnings came out today [2].
These movements reflect the ongoing volatility in the healthcare sector, driven by various factors including earnings reports, market sentiment, and geopolitical events. Investors should continue to monitor these companies for further developments.
References:
[1] https://www.cnbc.com/2025/05/13/1-stock-we-just-initiated-and-3-others-get-nice-bumps-after-saudis-us-spending-spree.html
[2] https://www.benzinga.com/insights/movers/25/05/45392931/12-health-care-stocks-moving-in-tuesdays-after-market-session
[3] https://www.stocktitan.net/news/LUCY/innovative-eyewear-inc-reports-q1-2025-unaudited-financial-ufmaqq8mocwd.html

Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios